Status:

WITHDRAWN

Use of Antibiotic Based Irrigation for Ureteroscopic Treatment of Urolithiasis

Lead Sponsor:

Yale University

Conditions:

Urinary Tract Infections

Sepsis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of the study is to investigate whether the use of gentamicin-based irrigation fluid during ureteroscopy decreases the risk of UTIs and other post-operative infections after surgery.

Detailed Description

The primary objective of this study is to determine whether the utilization of gentamicin-based irrigation fluid during ureteroscopy decreases the rate of 30-day post-operative symptomatic urinary tra...

Eligibility Criteria

Inclusion

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosed with urolithiasis (obstructing ureteral stone, large non-obstructing renal stones) warranting surgical intervention in line with American Urological Association guidelines for urolithiasis
  • At a higher risk for infectious complications following ureteroscopy based on a history of atleast one of the below:
  • 3 more urinary tract infections over 12 month period not on suppressive antibiotic therapy
  • Prior infectious complication following ureteroscopy
  • Placement of ureteral stent in the setting of obstructing ureteral stone with concern for superimposed urinary tract infection
  • Positive pre-operative urine culture treated with culture-appropriate antimicrobial therapy
  • Planned for cystoscopy, ureteroscopy with possible laser lithotripsy, and ureteral stent placement
  • For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 8 weeks after the end of gentamicin administration. Female patients of reproductive potential will have pregnancy screen prior to surgery per standard operating room protocol.
  • For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner

Exclusion

  • Estimated Glomerular Filtration Rate less than 60 mL/min
  • History of sensorineural hearing loss, vertigo, idiopathic dizziness
  • Active pregnancy or currently lactating
  • Known allergic reactions to components of gentamicin
  • Administration of intravenous gentamicin as part of surgical antibiotic prophylaxis

Key Trial Info

Start Date :

October 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2025

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT06007352

Start Date

October 1 2024

End Date

October 1 2025

Last Update

January 16 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Yale New Haven Health

New Haven, Connecticut, United States, 06510